SG11201804936UA - Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels - Google Patents
Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channelsInfo
- Publication number
- SG11201804936UA SG11201804936UA SG11201804936UA SG11201804936UA SG11201804936UA SG 11201804936U A SG11201804936U A SG 11201804936UA SG 11201804936U A SG11201804936U A SG 11201804936UA SG 11201804936U A SG11201804936U A SG 11201804936UA SG 11201804936U A SG11201804936U A SG 11201804936UA
- Authority
- SG
- Singapore
- Prior art keywords
- new jersey
- international
- pike
- pennsylvania
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
EN N R (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/106226 Al 22 June 2017 (22.06.2017) WIPO I PCT (51) International Patent Classification: CO7D 285/08 (2006.01) A61K 31/4196 (2006.01) CO7D 417/12 (2006.01) A61K 31/551 (2006.01) CO7D 277/52 (2006.01) A61P 29/00 (2006.01) A61K 31/4168 (2006.01) A61P 11/14 (2006.01) A61K 31/4178 (2006.01) (21) International Application Number: PCT/US2016/066445 (22) International Filing Date: 14 December 2016 (14.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/269,327 18 December 2015 (18.12.2015) US 62/290,235 2 February 2016 (02.02.2016) US 62/420,956 11 November 2016 (11.11.2016) US (71) Applicant (for all designated States except US): MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (72) Inventors; and (71) Applicants NZ, US only): GRESHOCK, Thomas, J. [US/US]; 770 Surrmeytown Pike, West Point, Pennsylvania 19486 (US). MULHEARN, James [US/US]; 770 Sum- neytown Pike, West Point, Pennsylvania 19486 (US). ZHENG, Junying [US/US]; 31 Newcomb Drive, New Providence, New Jersey 07074 (US). KIM, Ronald, M. [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jer- sey 07033 (US). ZHANG, Ting [CN/US]; 126 East Lin- coln Avenue, Rahway, New Jersey 07065-0907 (US). ROECKER, Anthony, J. [US/US]; 770 Surrmeytown Pike, West Point, Pennsylvania 19486 (US). WON, Wal- ter [US/US]; 950 Closter Rock Road, Alpine, New Jersey 08820 (US). NANTERMET, Philippe [US/US]; 770 Surrmeytown Pike, West Point, Pennsylvania 19486 (US). ANAND, Rajan [KE/US]; 22 Rainier Road, Fanwood, New Jersey 07012 (US). ZHOU, Gang [CN/US]; 111 Timothy Place, Bridgewater, New Jersey 08807 (US). WANG, Deping [US/US]; 770 Surrmeytown Pike, West Point, Pennsylvania 19486 (US). GUO, Liangqin [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jer- sey 07033 (US). (74) Common Representative: MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Decl arations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) [Continued on next page] = (54) Title: HYDROXYALKYLAMINE- AND HYDROXYCYCLOALKYLAMINE-SUBSTITUTED DIAMINE-ARYLSULFON- - AMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS (A) (57) : Disclosed are compounds of Formula A, or a salt thereof: Formula (A) wherein R I , R 2 , and E are defined herein, which compounds have properties for inhibiting Na„ 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating pain disorders, cough, and itch using the same. 1111111111111101110101011111010111110111010110111111011101111111111111111110111111 W O 20 17 / 106 226 Al WO 2017/106226 Al 1#1101M01101DEIROIDEOM0101101101011101111MOVOIMIE as to the applicant's entitlement to claim the priority of Published: the earlier application (Rule 4.17(iii)) — with international search report (Art. 21(3))
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562269327P | 2015-12-18 | 2015-12-18 | |
US201662290235P | 2016-02-02 | 2016-02-02 | |
US201662420956P | 2016-11-11 | 2016-11-11 | |
PCT/US2016/066445 WO2017106226A1 (en) | 2015-12-18 | 2016-12-14 | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804936UA true SG11201804936UA (en) | 2018-07-30 |
Family
ID=57708830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804936UA SG11201804936UA (en) | 2015-12-18 | 2016-12-14 | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
Country Status (27)
Country | Link |
---|---|
US (2) | US10221167B2 (en) |
EP (1) | EP3390374B1 (en) |
JP (1) | JP6572392B2 (en) |
KR (1) | KR20180095598A (en) |
CN (1) | CN108699015A (en) |
AR (1) | AR106987A1 (en) |
AU (1) | AU2016370554B2 (en) |
BR (1) | BR112018012327A2 (en) |
CA (1) | CA3008611A1 (en) |
CL (1) | CL2018001640A1 (en) |
CO (1) | CO2018006137A2 (en) |
CR (1) | CR20180322A (en) |
DO (1) | DOP2018000150A (en) |
EA (1) | EA201891313A1 (en) |
EC (1) | ECSP18052850A (en) |
HK (1) | HK1255027A1 (en) |
IL (1) | IL260052A (en) |
MX (1) | MX2018007450A (en) |
NI (1) | NI201800067A (en) |
PE (1) | PE20181495A1 (en) |
PH (1) | PH12018501288A1 (en) |
SG (1) | SG11201804936UA (en) |
SV (1) | SV2018005708A (en) |
TN (1) | TN2018000195A1 (en) |
TW (1) | TW201726637A (en) |
WO (1) | WO2017106226A1 (en) |
ZA (1) | ZA201803591B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI773657B (en) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists |
AU2016370677A1 (en) * | 2015-12-18 | 2018-06-07 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
TN2018000195A1 (en) * | 2015-12-18 | 2019-10-04 | Merck Sharp & Dohme | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
RU2019114964A (en) | 2016-10-17 | 2020-11-17 | Дженентек, Инк. | THERAPEUTIC AGENTS AND METHODS OF THEIR APPLICATION |
ES2897998T3 (en) * | 2016-10-27 | 2022-03-03 | Bristol Myers Squibb Co | NaV1.7 acylsulfonamide inhibitors |
WO2018093694A1 (en) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
AR114263A1 (en) | 2018-02-26 | 2020-08-12 | Genentech Inc | THERAPEUTIC COMPOUNDS AND METHODS TO USE THEM |
CN111936494A (en) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | Substituted hydro-pyrido-azines as sodium channel inhibitors |
KR20210054510A (en) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
CN111285825B (en) * | 2018-12-10 | 2023-02-17 | 中国科学院上海药物研究所 | Benzene sulfonamide substituted derivative, preparation method and application thereof |
WO2020248123A1 (en) * | 2019-06-11 | 2020-12-17 | Merck Sharp & Dohme Corp. | Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
CN113527281B (en) * | 2020-04-20 | 2023-12-22 | 昆山彭济凯丰生物科技有限公司 | Heterocyclic compounds, process for their preparation and their use |
CN117362206B (en) * | 2023-12-08 | 2024-02-20 | 四川大学华西第二医院 | Aryl sulfonamide compound, synthetic method and application |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
US9278088B2 (en) | 2002-02-19 | 2016-03-08 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
NZ545710A (en) * | 2003-08-08 | 2010-02-26 | Vertex Pharma | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
EP2073806B1 (en) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
US8853250B2 (en) | 2007-07-13 | 2014-10-07 | Icagen, Inc. | Sodium channel inhibitors |
CA2741029A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
PT2385938E (en) | 2009-01-12 | 2015-06-02 | Pfizer Ltd | Sulfonamide derivatives |
AR077252A1 (en) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | ESPIROOXINDOL COMPOUND ENANTIOMERS AND THEIR USES AS THERAPEUTIC AGENTS |
RU2544852C2 (en) | 2009-10-14 | 2015-03-20 | Ксенон Фармасьютикалз Инк. | Method for synthesis of spiro-oxyindole compounds |
BR112012021086A2 (en) | 2010-02-26 | 2016-05-17 | Xenon Pharmaceuticals Inc | pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
CA2804173C (en) | 2010-07-09 | 2015-01-13 | Pfizer Limited | Sulfonamide nav1.7 inhibitors |
EP2590957B1 (en) | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
US8592692B2 (en) | 2011-07-22 | 2013-11-26 | Tyco Electronics Corporation | Substrate having a plural diameter via |
US9079902B2 (en) | 2011-08-17 | 2015-07-14 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
AU2012328561A1 (en) | 2011-10-28 | 2014-04-17 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
JP6014154B2 (en) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
EP2800740A1 (en) | 2012-01-04 | 2014-11-12 | Pfizer Limited | N-aminosulfonyl benzamides |
US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
WO2013177224A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
WO2014008458A2 (en) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
US9376429B2 (en) | 2012-10-15 | 2016-06-28 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
EP2911663B1 (en) | 2012-10-26 | 2020-03-18 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
RU2015119635A (en) | 2012-10-26 | 2016-12-20 | Мерк Шарп И Доум Корп. | COMPOUNDS OF BENZOXAZOLINONE WITH SELECTIVE ACTIVITY IN POTENTIAL DEPENDENT SODIUM CHANNELS |
JP2014101287A (en) | 2012-11-16 | 2014-06-05 | Daiichi Sankyo Co Ltd | Indole derivative |
EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | Substituted triazolopyridines and methods of use thereof |
WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
BR112015022096A8 (en) | 2013-03-15 | 2019-11-26 | Chromocell Corp | sodium channel modulating compounds, composition comprising them and use thereof |
WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
MX368728B (en) | 2013-07-10 | 2019-10-14 | Vertex Pharma | Fused piperidine amides as modulators of ion channels. |
CN103389108B (en) | 2013-07-30 | 2016-02-24 | 邢皓宇 | A kind of electronic pedometer |
UA120353C2 (en) | 2013-09-10 | 2019-11-25 | Хромоселл Корпорейшн | Sodium channel modulators for the treatment of pain and diabetes |
WO2015051043A1 (en) | 2013-10-01 | 2015-04-09 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
PE20161247A1 (en) | 2013-11-27 | 2016-11-30 | Genentech Inc | SUBSTITUTED BENZAMIDES AND METHODS FOR USING THEM |
WO2015077905A1 (en) * | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
WO2015151001A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Sulfonamide compounds as voltage gated sodium channel modulators |
US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
TN2018000195A1 (en) * | 2015-12-18 | 2019-10-04 | Merck Sharp & Dohme | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
AU2016370677A1 (en) | 2015-12-18 | 2018-06-07 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
US10442778B2 (en) | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
WO2018093694A1 (en) | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
-
2016
- 2016-12-14 TN TNP/2018/000195A patent/TN2018000195A1/en unknown
- 2016-12-14 CN CN201680081234.0A patent/CN108699015A/en active Pending
- 2016-12-14 US US15/378,465 patent/US10221167B2/en active Active
- 2016-12-14 AU AU2016370554A patent/AU2016370554B2/en not_active Ceased
- 2016-12-14 BR BR112018012327A patent/BR112018012327A2/en not_active Application Discontinuation
- 2016-12-14 CR CR20180322A patent/CR20180322A/en unknown
- 2016-12-14 SG SG11201804936UA patent/SG11201804936UA/en unknown
- 2016-12-14 CA CA3008611A patent/CA3008611A1/en not_active Abandoned
- 2016-12-14 AR ARP160103829A patent/AR106987A1/en unknown
- 2016-12-14 PE PE2018001100A patent/PE20181495A1/en unknown
- 2016-12-14 JP JP2018531094A patent/JP6572392B2/en not_active Expired - Fee Related
- 2016-12-14 KR KR1020187020090A patent/KR20180095598A/en active IP Right Grant
- 2016-12-14 EP EP16820497.2A patent/EP3390374B1/en active Active
- 2016-12-14 WO PCT/US2016/066445 patent/WO2017106226A1/en active Application Filing
- 2016-12-14 EA EA201891313A patent/EA201891313A1/en unknown
- 2016-12-14 TW TW105141337A patent/TW201726637A/en unknown
- 2016-12-14 MX MX2018007450A patent/MX2018007450A/en unknown
-
2018
- 2018-05-30 ZA ZA2018/03591A patent/ZA201803591B/en unknown
- 2018-06-12 NI NI201800067A patent/NI201800067A/en unknown
- 2018-06-13 SV SV2018005708A patent/SV2018005708A/en unknown
- 2018-06-14 PH PH12018501288A patent/PH12018501288A1/en unknown
- 2018-06-14 IL IL260052A patent/IL260052A/en unknown
- 2018-06-15 CL CL2018001640A patent/CL2018001640A1/en unknown
- 2018-06-15 CO CONC2018/0006137A patent/CO2018006137A2/en unknown
- 2018-06-18 DO DO2018000150A patent/DOP2018000150A/en unknown
- 2018-07-12 EC ECSENADI201852850A patent/ECSP18052850A/en unknown
- 2018-11-06 HK HK18114148.2A patent/HK1255027A1/en unknown
-
2019
- 2019-01-11 US US16/246,068 patent/US20190233406A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SV2018005708A (en) | 2018-12-14 |
EA201891313A1 (en) | 2018-11-30 |
US20190233406A1 (en) | 2019-08-01 |
TW201726637A (en) | 2017-08-01 |
PH12018501288A1 (en) | 2019-01-28 |
CA3008611A1 (en) | 2017-06-22 |
AU2016370554B2 (en) | 2018-11-29 |
TN2018000195A1 (en) | 2019-10-04 |
CR20180322A (en) | 2018-08-21 |
PE20181495A1 (en) | 2018-09-18 |
MX2018007450A (en) | 2018-11-14 |
ZA201803591B (en) | 2019-04-24 |
EP3390374A1 (en) | 2018-10-24 |
KR20180095598A (en) | 2018-08-27 |
JP6572392B2 (en) | 2019-09-11 |
WO2017106226A1 (en) | 2017-06-22 |
BR112018012327A2 (en) | 2018-12-04 |
US10221167B2 (en) | 2019-03-05 |
NI201800067A (en) | 2018-07-24 |
CO2018006137A2 (en) | 2018-07-10 |
AR106987A1 (en) | 2018-03-07 |
CN108699015A (en) | 2018-10-23 |
DOP2018000150A (en) | 2018-07-31 |
EP3390374B1 (en) | 2020-08-26 |
AU2016370554A1 (en) | 2018-06-14 |
IL260052A (en) | 2018-07-31 |
CL2018001640A1 (en) | 2018-08-03 |
US20170174674A1 (en) | 2017-06-22 |
ECSP18052850A (en) | 2018-12-31 |
HK1255027A1 (en) | 2019-08-02 |
JP2019502681A (en) | 2019-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804936UA (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201804363UA (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201810143PA (en) | Exon skipping oligomers for muscular dystrophy | |
SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
SG11201809162XA (en) | 6-aminopyridin-3-yl thiazoles as modulators of ror?t | |
SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201806783WA (en) | Methods for treatment and prophylaxis of hiv and aids |